Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate SON-080 for the treatment of diabetic peripheral neuropathy in India.
| Subscribe To Our Free Newsletter |
